Extension of the Cancer Immunotherapy Pilot Program, 28645-28646 [2017-13122]

Download as PDF asabaliauskas on DSKBBXCHB2PROD with NOTICES Federal Register / Vol. 82, No. 120 / Friday, June 23, 2017 / Notices profit organizations and the private sector; and other matters as described in the agenda found on the OEAB Web site at http://oeab.noaa.gov. DATES: The announced meeting is scheduled for Tuesday, July 11, 2017 from 9:00 a.m. to 5:00 p.m. EDT and Wednesday, July 12, 2017 from 9:00 to 5:00 p.m. EDT. ADDRESSES: The meeting will be held at Oceaneering Advanced Technologies, 7001 Dorsey Road, Hanover, Maryland 21076. FOR FURTHER INFORMATION CONTACT: Mr. David McKinnie, Designated Federal Officer, Ocean Exploration Advisory Board, National Oceanic and Atmospheric Administration, 7600 Sand Point Way NE., Seattle, WA 98115, (206) 526–6950. SUPPLEMENTARY INFORMATION: NOAA established the OEAB under the Federal Advisory Committee Act (FACA) and legislation that gives the agency statutory authority to operate an ocean exploration program and to coordinate a national program of ocean exploration. The OEAB advises NOAA leadership on strategic planning, exploration priorities, competitive ocean exploration grant programs and other matters as the NOAA Administrator requests. OEAB members represent government agencies, the private sector, academic institutions, and not-for-profit institutions involved in all facets of ocean exploration—from advanced technology to citizen exploration. In addition to advising NOAA leadership, NOAA expects the OEAB to help to define and develop a national program of ocean exploration—a network of stakeholders and partnerships advancing national priorities for ocean exploration. Status: The meeting will be open to the public with a 15-minute public comment period on Tuesday, July 11, 2017 from 11:45 a.m. to 12:00 p.m. EDT (please check the final agenda on the Web site to confirm the time). The public may listen to the meeting and provide comments during the public comment period via teleconference. Dial-in information may be found on the meeting agenda posted to the OEAB Web site http://oeab.noaa.gov. The OEAB expects that public statements at its meetings will not be repetitive of previously submitted verbal or written statements. In general, each individual or group making a verbal presentation will be limited to three minutes. The Designated Federal Officer must receive written comments by July 3, 2017 to provide sufficient time for OEAB review. Written VerDate Sep<11>2014 19:21 Jun 22, 2017 Jkt 241001 comments received after July 3, 2017 will be distributed to the OEAB but may not be reviewed prior to the meeting date. Seats will be available on a firstcome, first-served basis. Special Accomodations: These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to David McKinnie, Designated Federal Officer (see below) by July 3, 2017. Dated: June 9, 2017. David Holst, Acting Chief Financial Officer/CAO, Office of Oceanic and Atmospheric Research, National Oceanic and Atmospheric Administration. [FR Doc. 2017–13200 Filed 6–22–17; 8:45 am] BILLING CODE 3510–KA–P DEPARTMENT OF COMMERCE National Oceanic and Atmospheric Administration RIN 0648–XF496 Caribbean Fishery Management Council; Public Meeting National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce. ACTION: Notice of a public meeting. AGENCY: The Caribbean Fishery Management Council’s District Advisory Panels (DAPs) for Puerto Rico, St. Croix and St. Thomas/St. John, USVI, will hold a joint meeting. DATES: The meeting will be held on Thursday, July 6, 2017, from 9:30 a.m. to 5 p.m. ADDRESSES: The meeting will be held at the Verdanza Hotel, Tartak St., Isla Verde, Puerto Rico. FOR FURTHER INFORMATION CONTACT: Caribbean Fishery Management Council, ˜ 270 Munoz Rivera Avenue, Suite 401, San Juan, Puerto Rico 00918, telephone: (787) 766–5926. SUPPLEMENTARY INFORMATION: The DAPs will meet to discuss the items contained in the following agenda: July 6, 2017, 9 a.m. —Call to Order and Welcome—Miguel ´ A. Rolon —General Concepts (Scalars, Buffers, Scientific Uncertainty) to be Considered for Discussion by the DAPs—Dr. Richard Appeldoorn —Expected Outcomes for Submission to the SSC and the CFMC—Dr. Richard Appeldoorn —Quality of Information —Year Sequences SUMMARY: PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 28645 —Life History Parameters —Buffers Between ABCs and ACLs 10:30 a.m.—Coffee Break 10:45 a.m.–12 noon Separate Meetings of Each DAP —Year Sequences —Recommended Buffers Between ABC and ACL 12 p.m.–1:30 p.m.—Lunch Break 1:30 p.m.–3:30 p.m. DAPs Continuation of Morning Discussions 3:30 p.m.–4:30 p.m. Reports by DAPs Chairs on DAPs Discussions and Recommendations —Conclusion and Recommendations to CFMC 4:30 p.m.–5 p.m. —Other Business The meeting is open to the public, and will be conducted in English. Fishers and other interested persons are invited to attend and participate with oral or written statements regarding agenda issues. Special Accommodations This meeting is physically accessible to people with disabilities. For more information or request for sign language interpretation and/other auxiliary aids, ´ please contact Mr. Miguel A. Rolon, Executive Director, Caribbean Fishery ˜ Management Council, 270 Munoz Rivera Avenue, Suite 401, San Juan, Puerto Rico, 00918, telephone (787) 766–5926, at least 5 days prior to the meeting date. Dated: June 20, 2017. Tracey L. Thompson, Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 2017–13151 Filed 6–22–17; 8:45 am] BILLING CODE 3510–22–P DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO–P–2017–0026] Extension of the Cancer Immunotherapy Pilot Program United States Patent and Trademark Office, Commerce. ACTION: Notice. AGENCY: On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented the Cancer Immunotherapy Pilot Program, which permits patent applications pertaining to cancer immunotherapy to be advanced out of turn for examination and reviewed earlier (accorded special status). To date, over 80 petitions SUMMARY: E:\FR\FM\23JNN1.SGM 23JNN1 asabaliauskas on DSKBBXCHB2PROD with NOTICES 28646 Federal Register / Vol. 82, No. 120 / Friday, June 23, 2017 / Notices requesting participation in the pilot program have been filed, and 9 patents have been granted under the pilot program. Various stakeholders from around the world have filed petitions to participate in the pilot program—they are independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies. The pilot program was originally scheduled to end on June 28, 2017. In view of the continued interest in the pilot program, the USPTO is extending the pilot program until December 31, 2018. All pilot parameters will remain the same as the original pilot. DATES: Effective Date: June 23, 2017. Duration: The Cancer Immunotherapy Pilot Program will continue to run until December 31, 2018. Therefore, petitions to make special under the Cancer Immunotherapy Pilot Program must be filed on or before December 31, 2018. The USPTO may further extend the pilot program (with or without modifications) or terminate it depending on feedback received, continued interest and the effectiveness of the pilot program. FOR FURTHER INFORMATION CONTACT: Pinchus M. Laufer, Patent Attorney (telephone (571) 272–7726; electronic mail at pinchus.laufer@uspto.gov) or Susy Tsang-Foster, Senior Legal Advisor (telephone (571) 272–7711; electronic mail at susy.tsang-foster@uspto.gov), of the Office of Patent Legal Administration, Office of the Deputy Commissioner for Patent Examination Policy. For questions relating to a specific petition, please contact Gary B. Nickol, Supervisory Patent Examiner (telephone (571) 272–0835; electronic mail at gary.nickol@uspto.gov) or Brandon J. Fetterolf, Supervisory Patent Examiner (telephone (571) 272–2919; electronic mail at brandon.fetterolf@uspto.gov), of Technology Center 1600. SUPPLEMENTARY INFORMATION: The USPTO published a notice for the implementation of the Cancer Immunotherapy Pilot Program on June 29, 2016. See Cancer Immunotherapy Pilot Program, 81 FR 42328 (June 29, 2016), 1428 Off. Gaz. Pat. Office 253 (July 26, 2016) (Cancer Immunotherapy Notice). The pilot program was designed to support the global fight against cancer. The Cancer Immunotherapy Notice indicated that an applicant may have an application advanced out of turn (accorded special status) for examination without meeting all of the current requirements of the accelerated examination program set forth in item VIII of MPEP section 708.02(a), if the VerDate Sep<11>2014 19:21 Jun 22, 2017 Jkt 241001 application contained at least one claim to a method of treating cancer using immunotherapy and met other requirements specified in the Cancer Immunotherapy Notice. The Cancer Immunotherapy Notice established that the pilot program would run for twelve months from June 29, 2016. The USPTO is hereby extending the pilot program through December 31, 2018 in view of the continued interest in the pilot program. The extension also will allow the USPTO to continue its evaluation of the pilot program. The requirements of the pilot program have not been modified. Various stakeholders from around the world have filed petitions to participate in the pilot program—they are independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies. To date, over 80 petitions requesting participation in the pilot program have been filed, and 9 patents have been granted under the pilot program. The USPTO may again extend the pilot program (with or without modifications) depending on the feedback from the participants, continued interest, and the effectiveness of the pilot program. Dated: June 19, 2017. Joseph Matal, Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. 2017–13122 Filed 6–22–17; 8:45 am] protests must be filed on or before the comment date. Anyone filing a motion to intervene or protest must serve a copy of that document on the Applicant and all the parties in this proceeding. The Commission encourages electronic submission of protests and interventions in lieu of paper using the eFiling link at http://www.ferc.gov. Persons unable to file electronically should submit an original and 5 copies of the protest or intervention to the Federal Energy Regulatory Commission, 888 First Street NE., Washington, DC 20426. This filing is accessible on-line at http://www.ferc.gov, using the ‘‘eLibrary’’ link and is available for electronic review in the Commission’s Public Reference Room in Washington, DC. There is an eSubscription link on the Web site that enables subscribers to receive email notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please email FERCOnlineSupport@ferc.gov, or call (866) 208–3676 (toll free). For TTY, call (202) 502–8659. Comment Date: 5:00 p.m. Eastern Time on June 26, 2017. Dated: June 19, 2017. Nathaniel J. Davis, Sr., Deputy Secretary. [FR Doc. 2017–13111 Filed 6–22–17; 8:45 am] BILLING CODE 6717–01–P DEPARTMENT OF ENERGY BILLING CODE 3510–16–P Federal Energy Regulatory Commission DEPARTMENT OF ENERGY [Project No. 2368–056] Federal Energy Regulatory Commission Algonquin Northern Maine Generating Company; Notice of Intent to File License Application, Filing of PreApplication Document (Pad), Intent To Waive Certain Procedural Matters, Commencement of Pre-Filing Process, and Scoping; Request for Comments on the Pad and Scoping Document, and Identification of Issues and Associated Study Requests [Docket No. NJ17–10–001] Notice of Filing; City of Dover, Delaware Take notice that on June 15, 2017, City of Dover, Delaware submitted its Supplement to the May 16, 2017 tariff filing (Deficiency Filing). Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission’s Rules of Practice and Procedure (18 CFR 385.211, 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 a. Type of Filing: Notice of Intent to File License Application for a New License and Commencing Pre-filing Process. b. Project No.: 2368–056. c. Dated Filed: May 1, 2017. d. Submitted By: Algonquin Northern Maine Generating Company (Algonquin). e. Name of Project: Squa Pan Hydroelectric Project. f. Location: On Scopan Stream near the town of Masardis in Aroostook E:\FR\FM\23JNN1.SGM 23JNN1

Agencies

[Federal Register Volume 82, Number 120 (Friday, June 23, 2017)]
[Notices]
[Pages 28645-28646]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-13122]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2017-0026]


Extension of the Cancer Immunotherapy Pilot Program

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: On June 29, 2016, the United States Patent and Trademark 
Office (USPTO) implemented the Cancer Immunotherapy Pilot Program, 
which permits patent applications pertaining to cancer immunotherapy to 
be advanced out of turn for examination and reviewed earlier (accorded 
special status). To date, over 80 petitions

[[Page 28646]]

requesting participation in the pilot program have been filed, and 9 
patents have been granted under the pilot program. Various stakeholders 
from around the world have filed petitions to participate in the pilot 
program--they are independent inventors, universities, research 
institutions, hospitals, medical centers, government agencies, and 
large and small companies. The pilot program was originally scheduled 
to end on June 28, 2017. In view of the continued interest in the pilot 
program, the USPTO is extending the pilot program until December 31, 
2018. All pilot parameters will remain the same as the original pilot.

DATES: Effective Date: June 23, 2017.
    Duration: The Cancer Immunotherapy Pilot Program will continue to 
run until December 31, 2018. Therefore, petitions to make special under 
the Cancer Immunotherapy Pilot Program must be filed on or before 
December 31, 2018. The USPTO may further extend the pilot program (with 
or without modifications) or terminate it depending on feedback 
received, continued interest and the effectiveness of the pilot 
program.

FOR FURTHER INFORMATION CONTACT: Pinchus M. Laufer, Patent Attorney 
(telephone (571) 272-7726; electronic mail at pinchus.laufer@uspto.gov) 
or Susy Tsang-Foster, Senior Legal Advisor (telephone (571) 272-7711; 
electronic mail at susy.tsang-foster@uspto.gov), of the Office of 
Patent Legal Administration, Office of the Deputy Commissioner for 
Patent Examination Policy.
    For questions relating to a specific petition, please contact Gary 
B. Nickol, Supervisory Patent Examiner (telephone (571) 272-0835; 
electronic mail at gary.nickol@uspto.gov) or Brandon J. Fetterolf, 
Supervisory Patent Examiner (telephone (571) 272-2919; electronic mail 
at brandon.fetterolf@uspto.gov), of Technology Center 1600.

SUPPLEMENTARY INFORMATION: The USPTO published a notice for the 
implementation of the Cancer Immunotherapy Pilot Program on June 29, 
2016. See Cancer Immunotherapy Pilot Program, 81 FR 42328 (June 29, 
2016), 1428 Off. Gaz. Pat. Office 253 (July 26, 2016) (Cancer 
Immunotherapy Notice). The pilot program was designed to support the 
global fight against cancer. The Cancer Immunotherapy Notice indicated 
that an applicant may have an application advanced out of turn 
(accorded special status) for examination without meeting all of the 
current requirements of the accelerated examination program set forth 
in item VIII of MPEP section 708.02(a), if the application contained at 
least one claim to a method of treating cancer using immunotherapy and 
met other requirements specified in the Cancer Immunotherapy Notice.
    The Cancer Immunotherapy Notice established that the pilot program 
would run for twelve months from June 29, 2016. The USPTO is hereby 
extending the pilot program through December 31, 2018 in view of the 
continued interest in the pilot program. The extension also will allow 
the USPTO to continue its evaluation of the pilot program. The 
requirements of the pilot program have not been modified.
    Various stakeholders from around the world have filed petitions to 
participate in the pilot program--they are independent inventors, 
universities, research institutions, hospitals, medical centers, 
government agencies, and large and small companies. To date, over 80 
petitions requesting participation in the pilot program have been 
filed, and 9 patents have been granted under the pilot program. The 
USPTO may again extend the pilot program (with or without 
modifications) depending on the feedback from the participants, 
continued interest, and the effectiveness of the pilot program.

    Dated: June 19, 2017.
Joseph Matal,
Performing the Functions and Duties of the Under Secretary of Commerce 
for Intellectual Property and Director of the United States Patent and 
Trademark Office.
[FR Doc. 2017-13122 Filed 6-22-17; 8:45 am]
BILLING CODE 3510-16-P